In order to ensure stable treated water quality and to reduce chemical costs in any treatment plant it is necessary to study and optimize the coagulant dosing control (CDC). This research focused on the affects of coagulant in the integrated membrane (UF & RO) system employed for industrial water production. The dose of coagulant (PACl) might be associated (partly) with the frequency of cleaning in the RO units, and a value of 20 abs/m in the UF permeate is the control of the dosage process. This could suggest that organic fouling is directly and indirectly (inducing biofouling as well) the cause of fouling of the RO membranes. Nevertheless, high doses of PACl could produce scaling of aluminium and, in this work minimizing PACl to prevent operational problems in RO membranes was focused. The approach involved the study of the treatment processes, determination of the optimum dose of coagulant, evaluation of the removal efficiency of UV and DOC by coagulation. The available data, which comprised monthly/weekly measurements for a period of six years of operation, was studied and analyzed and an attempt was made to draw some conclusions for the plant regarding the coagulant dosage and the link with UV absorbance as control. The study of the coagulant dosing control revealed that the use of simple and robust online sensors like UV measurement allows an automatic dosing control although this parameter is not found to be sufficient to fully characterize nor predict fouling during membrane operation and there is no link between UV after the UF and the cleaning frequency of the RO. Parameters, as the added value allowed to verify the doses efficiencies in UV and DOC removal. Coagulant dose depends on the level of UV absorbance in the UF permeate and it should never be higher than 20 abs/m to ensure a RO cleaning frequency as long as possible. However, it was found that the target value of 20 abs/m produced substantial over dose of coagulant - 90% of the time - when UV removal is considered only. In the same way, for coagulant doses in excess of 5 mg/L, the additional removal of UV is less than 2.5% per mg coagulant/L, which suggests that the current dose is on the high side. Furthermore, a coagulant dose in excess of 5 mg/L did not produce significant additional UV removal, and thus a reduction from 14 mg/L (2005 dose) to ca. 7 mg/L could be considered.